This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dias, V. C. Articles by Ellenbogen, K. A. Search for Related Content PubMed PubMed Citation Articles by Dias, V. C. Articles by Ellenbogen, K. A.

Circulation, Vol 86, 1421-1428, Copyright © 1992 by American Heart Association

ARTICLES

Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter

VC Dias, SJ Weir and KA Ellenbogen
Department of Clinical Research, Marion Merrell Dow Inc., Kansas City, Mo 64134-0627.

BACKGROUND. Diltiazem, a calcium channel blocker, has been shown to be safe and effective in the treatment of patients in atrial fibrillation and/or atrial flutter. However, there have been no pharmacokinetic/pharmacodynamic studies of diltiazem in these patients. METHODS AND RESULTS. The pharmacokinetics and pharmacodynamics of intravenous diltiazem were determined in 32 patients with atrial fibrillation or atrial flutter (mean +/- SD age, 66 +/- 7 years; mean baseline heart rate, 131 +/- 10 beats per minute) after 20 mg or 20 mg followed by 25-mg bolus doses and a 10 and 15 mg/hr infusion for 24 hours. After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively. Percentages of the plasma concentrations of the principal metabolites desacetyldiltiazem and N-desmethyldiltiazem to diltiazem were < 15% and < 10%, respectively. Thirty of 32 patients maintained response throughout the 24-hour infusion of diltiazem. Using a sigmoidal Emax pharmacodynamic model, a strong relation (mean +/- SD r2, 0.78 +/- 0.2) was observed between plasma diltiazem concentration and percent heart rate reduction. Mean +/- SD Emax (maximum percent reduction in heart rate from baseline) and EC50 (plasma diltiazem concentration that achieves half Emax) were 52 +/- 17% and 110 +/- 84 ng/ml, respectively. The model predicts that mean plasma diltiazem concentration of 79, 172, and 294 ng/ml are required to produce a 20%, 30%, and 40% reduction in heart rate, respectively. A relation between plasma diltiazem concentration and percent change in systolic blood pressure (SBP) or diastolic blood pressure (DBP) from baseline was not observed (mean +/- SD r2, SBP/DBP: 0.35 +/- 0.24/0.36 +/- 0.2). There were no untoward side effects observed. CONCLUSIONS. First, the pharmacokinetics of diltiazem in patients with atrial fibrillation or atrial flutter is nonlinear with an apparent dose-dependent decrease in systemic clearance with increasing infusion rate. Second, using a sigmoidal Emax model, there is a strong relation between plasma diltiazem concentration and percent heart rate reduction. Third, the plasma concentrations of the principal metabolites desacetyldiltiazem and N- desmethyldiltiazem are low and are not expected to contribute significantly to the pharmacodynamics of intravenous diltiazem in these patients.

This article has been cited by other articles:

				C Demircan, H I Cikriklar, Z Engindeniz, H Cebicci, N Atar, V Guler, E O Unlu, and B Ozdemir Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation Emerg. Med. J., June 1, 2005; 22(6): 411 - 414. [Abstract] [Full Text] [PDF]

				D. Amar and M. Fleisher Diltiazem Treatment Does Not Alter Renal Function After Thoracic Surgery Chest, May 1, 2001; 119(5): 1476 - 1479. [Abstract] [Full Text] [PDF]

				D. Amar, N. Roistacher, V. W. Rusch, D. H. Y. Leung, I. Ginsburg, H. Zhang, M. S. Bains, R. J. Downey, R. J. Korst, and R. J. Ginsberg Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 790 - 798. [Abstract] [Full Text] [PDF]

				D. Amar, N. Roistacher, M. E. Burt, V. W. Rusch, M. S. Bains, D. H. Y. Leung, R. J. Downey, and R. J. Ginsberg Effects of Diltiazem Versus Digoxin on Dysrhythmias and Cardiac Function After Pneumonectomy Ann. Thorac. Surg., May 1, 1997; 63(5): 1374 - 1381. [Abstract] [Full Text]